Literature DB >> 33109402

The Prognostic Significance of C-reactive Protein-To-Lymphocyte Ratio in Colorectal Liver Metastases.

Tomohiko Taniai1, Koichiro Haruki2, Ryoga Hamura1, Yuki Fujiwara1, Kenei Furukawa1, Takeshi Gocho1, Hiroaki Shiba1, Katsuhiko Yanaga1.   

Abstract

BACKGROUND: The preoperative systemic inflammation has been reported to predict tumor recurrence and survival in various cancers, including colorectal liver metastases (CRLM). However, more sensitive biomarker is required to improve perioperative management of CRLM. Therefore, we developed a novel indicator; C-reactive protein-to-lymphocyte ratio (CLR). The aim of this study is to evaluate the prognostic significance of CLR in patients with CRLM after hepatic resection.
MATERIALS AND METHODS: The study comprised 197 patients who had undergone hepatic resection for CRLM between January 2000 and December 2018. We retrospectively investigated the relation between CLR and disease-free survival and overall survival after hepatic resection and compared their prognostic significance with that of the C-reactive protein-to-albumin ratio and neutrophil-to-lymphocyte ratio.
RESULTS: Optimal cutoff level of the CLR by receiver operating characteristics analysis was 62.8 × 10-6. By multivariate analysis, CLR was an independent predictor of disease-free survival [hazard ratio (HR): 1.463, 95% confidence interval (CI): 1.003-2.135, P = 0.048), whereas lymph node metastases>4 (HR: 1.804, 95% CI: 1.100-2.958, P = 0.019) and CLR (HR: 1.656, 95% CI: 1.007-2.724, P = 0.047) were independent predictors of overall survival, while the C-reactive protein-to-albumin ratio and neutrophil-to-lymphocyte ratio were not.
CONCLUSIONS: CLR may be an independent and significant indicator of poor long-term outcomes in patients with CRLM after hepatic resection.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CRP-to-lymphocyte ratio; Colorectal liver metastases; Hepatic resection; Prognosis

Year:  2020        PMID: 33109402     DOI: 10.1016/j.jss.2020.08.059

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  6 in total

1.  Prognostic Role of Lymphocyte-C-Reactive Protein Ratio in Colorectal Cancer: A Systematic Review and Meta Analysis.

Authors:  Xinglong He; Ade Su; Yongcheng Xu; Diaolong Ma; Guoyuan Yang; Yiyun Peng; Jin Guo; Ming Hu; Yuntao Ma
Journal:  Front Oncol       Date:  2022-07-06       Impact factor: 5.738

2.  High Neutrophil-To-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammation Index (SII) Are Markers of Longer Survival After Metastasectomy of Patients With Liver-Only Metastasis of Rectal Cancer.

Authors:  Nándor Polk; Barna Budai; Erika Hitre; Attila Patócs; Tamás Mersich
Journal:  Pathol Oncol Res       Date:  2022-04-27       Impact factor: 2.874

3.  The Novel Predictive Biomarkers for Type 2 Diabetes Mellitus in Active Pulmonary Tuberculosis Patients.

Authors:  Qi Yu; Wujin Weng; Hong Luo; Jisong Yan; Xin Zhao
Journal:  Infect Drug Resist       Date:  2022-08-13       Impact factor: 4.177

4.  A scoring system developed from a nomogram to differentiate active pulmonary tuberculosis from inactive pulmonary tuberculosis.

Authors:  Qi Yu; Jisong Yan; Shan Tian; Wujin Weng; Hong Luo; Gang Wei; Gangyu Long; Jun Ma; Fengyun Gong; Xiaorong Wang
Journal:  Front Cell Infect Microbiol       Date:  2022-09-02       Impact factor: 6.073

Review 5.  Which patients are prone to suffer liver metastasis? A review of risk factors of metachronous liver metastasis of colorectal cancer.

Authors:  Mengdi Hao; Kun Wang; Yuhan Ding; Huimin Li; Yin Liu; Lei Ding
Journal:  Eur J Med Res       Date:  2022-07-25       Impact factor: 4.981

6.  Clinical impact of lymphocyte/C-reactive protein ratio on postoperative outcomes in patients with rectal cancer who underwent curative resection.

Authors:  Takehito Yamamoto; Meiki Fukuda; Yoshihisa Okuchi; Yoshiki Oshimo; Yuta Nishikawa; Koji Hisano; Takayuki Kawai; Kohta Iguchi; Yukihiro Okuda; Ryo Kamimura; Eiji Tanaka; Hiroaki Terajima
Journal:  Sci Rep       Date:  2022-10-13       Impact factor: 4.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.